The top U.K.’s pharmaceutical regulatory agency said on Thursday that they did not found any evidence for blood clots caused by the coronavirus vaccine created by Astra Zeneca and the Oxford University, which was noticed in several people that received the vaccine in some European counties, according to The Hill.
The extremely low risk involved still outweighs the benefits of receiving the shot, said the Medicine and Healthcare products Regulatory Agency in a statement.
“”Our through and careful review, alongside the critical assessment of leading, independent scientists, shows that there is no evidence that that blood clots in veins is occurring more than would be expected in the absence of vaccination, for either vaccine,” said the chief executive of the regulatory agency, June Raine.
The agency reviewed only five cases of clotting among 11 million vaccinated Britons, and Raine said that the agency received reports of some rare form of blood clotting, a sinus vein thrombosis that occurs when someone who received the vaccine experienced a drop in platelets.
The reports of blood clotting caused dozen European countries to pause their use of the Astra Zeneca vaccine.
The report from the United Kingdom’s agency comes only a day after the World Health Organization gave its own support for the vaccine from Astra Zeneca, a vaccine that many European countries are relying on, given the fact that they are short on vaccine solutions.
Astra Zeneca came out with a number of only 40 persons who had developed blood clots from over 17 million vaccinated.
“Vaccination against COVID-19 will not reduce illness or deaths from other causes. Thromboembolic events are known to occur frequently. Venous thromboembolism is the third most common cardiovascular disease globally. At this time, WHO considers that the benefits of the Astra Zeneca vaccine outweigh its risks and recommends that vaccination continue,” said the WHO.
Be the first to comment